Metastatic Breast Cancer, Stage IV Breast Cancer
Conditions
Keywords
BP-C1, cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin, Benzene polycarboxylic acids complex with cis-diammineplatinum(II), Metastatic Breast Cancer, Platinum analogue, Metronomic chemotherapy, Breast cancer, Cisplatin
Brief summary
The purpose of this study is to determine whether BP-C1 is effective in the short-term treatment of metastatic breast cancer patients who have previously undergone at least three lines of chemotherapy.
Detailed description
BP-C1, solution for injection 0.05%, is currently being developed for treatment of patients with metastatic breast cancer with palliative intent. Active substance of the product, which is a novel platinum-containing anticancer agent developed for intramuscular administration, is а cis-diammineplatinum(II) complexed with a polymer containing benzene polycarboxylic acids derived from lignin. The amphiphilic characteristics of the polymer have resulted in a product with clear and significantly altered and improved properties compared to other platinum analogues, e.g. cisplatin, carboplatin and oxaliplatin. BP-C1 preserves antitumour activity of its predecessors (e.g. cisplatin and carboplatin), additionally offering the following advantages that ensure favourable outcome of treatment of metastatic breast cancer patients: * injectable solution (intramuscular) does not cause injection site reactions; can be administered at home by a nurse or a patient; * has an improved pharmacokinetic profile; * demonstrates efficacy comparable to cisplatin and much higher than carboplatin (in-vitro; in-vivo data); * exerts an additional immunomodulatory activity. This study is a randomised, double-blind, placebo-controlled, multicentre, phase IIb study in Thai patients with metastatic breast cancer. The eligible patients will be allocated (1:1) to either BP-C1 arm or Placebo arm and treated once daily for 32 days. The patients allocated to Placebo arm will cross over to BP-C1 treatment for 32 days when progression of the cancer will be documented and latest after 32-day treatment with Placebo. After 32-day treatment with BP-C1 the patients are invited to continue open-label treatment under protocol BMC2011-02.
Interventions
DRUGBP-C1
BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
DRUGPlacebo
Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
Sponsors
Meddoc
Norwegian University of Life Sciences
Meabco A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Female patients with histologically verified metastatic breast cancer (stage IV) with measurable metastases, between 18 and 80 years of age, who had undergone at least three lines of chemotherapy and had an expected survival time of at least 3 months.
Exclusion criteria
Patients fulfilling at least one of the following criteria will be excluded from participation in the study: * Abnormal liver function classified as total bilirubin \>34 μmol/L or ALAT \> 3 times of the upper limit of normal (ULN). In case of metastases in the liver, the ALAT limit for exclusion is set to 5хULN. * Abnormal kidney function defined by serum creatinine \>120 μmol/L. * Abnormal coagulation capacity defined by the relative arbitrary concentration of coagulation factors 2,7,10; INR \>1.5. * Verified metastases to the brain. * Synchronous cancer except for non- melanoma skin cancer and early stage of cervical cancer. * Abnormal hematology status defined by hemoglobin \< 9.0 g/dL, platelet count \< 100,000/mm\^3 or leucocytes \< 3 x 10\^9/L. * Clinically significant abnormal ECG. * Karnofsky performance status score \<60%. * Pregnant or breast feeding women. * Women of fertile age who do not want to be tested for possible pregnancy. * Fertile female who do not want to use safe protection against pregnancy, starting one month before the start of the study treatment and lasting at least six weeks after. * Uncontrolled bacterial, viral, fungal or parasite infection. * Under systemic treatment with corticosteroids or other immunosuppressive drugs in the last 21 days before start of the trial treatment. * Participating in another clinical trial with pharmaceuticals in the last six weeks before start of this trial treatment. * Not able to understand information. * Not willing or not able to give written consent to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change (%) in the sum of diameters of target lesions | baseline to Day 32 of treatment | Diameter of target lesions will be measured by computer tomography (CT) with contrasting using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of target lesions | baseline to Day 32 of treatment | Number of target lesions per each patient will be evaluated by CT with contrasting. Number of target lesions at baseline and Day 32 of treatment will be presented in shift tables. |
| Treatment response | baseline to Day 32 of treatment | In accordance with RECIST v1.1 the treatment response will be classified as 'complete response', 'partial response', 'stable disease' or 'progressive disease': Complete response (CR): disappearance of all target lesions. Partial response (PR): at least 30% decrease in the sum of longest diameters of target lesions, taking as reference the baseline sum of diameters. Progressive disease (PD): at least 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum might also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions will also be considered progression. Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| Karnofsky Performance Status (KPS) score | baseline to Day 16 and Day 32 of treatment | KPS describes an outcome in 11 grades, starting as normal without complaints and evidence of disease (equals 100 as the best) and dead (equals 0) as the lowest. KPS score will be assessed every 16 days during 32-day treatment period. |
| Separate scores of the general questionnaire EORTC QLQ-C30 | baseline to Day 16 and Day 32 of treatment | The EORTC QLQ-C30 is a general quality of life questionnaire for cancer patients. The questionnaire contains 30 questions. Three variables will be obtained from the EORTC QLQ-C30: the sum of scores C1 to C5 denoted as Physical activity problem last week, the sum of scores C6 to C28 denoted as Discomfort last week, and the sum of scores C29 and C30 denoted as Health and quality of life. |
| Separate scores of the specific questionnaire EORTC QLQ-BR23 | baseline to Day 16 and Day 32 of treatment | The EORTC QLQ-BR23 is a breast cancer-specific quality of life questionnaire. The questionnaire consists of 23 questions. Three variables will be obtained from the EORTC-BR23: the sum of scores BR1 to BR13 denoted as Breast cancer problem last week, the sum of scores BR14 to BR16 denoted as Sexual interest and activity last four weeks and the sum of scores BR17 to BR23 denoted as Breast cancer related pain and discomfort last week. |
| Maximum Common Toxicity Criteria (CTC) score | baseline to Day 16 and Day 32 of treatment | Maximum CTC score will be recorded using NCI Common Toxicity Criteria v2.0 divided in 15 categories. |
| Change in the Sum CTC score | baseline to Day 16 and Day 32 of treatment | The Sum CTC score will be a sum of all registered CTC scores by 15 categories. |
| Number of registered adverse events | baseline to Day 32 of treatment | Adverse events (AEs) will be coded according to the MedDRA (version 16.1E). AEs will be systemized by system organ class and by preferred term. AEs will be analyzed by severity, seriousness and relatedness to the drug. |
Countries
Thailand
Outcome results
None listed